1ST 104
Alternative Names: 1ST-104Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator 1St Biotherapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Multiple system atrophy
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in South Korea
- 28 Oct 2024 No recent reports of development identified for research development in Multiple system atrophy in South Korea
- 24 Sep 2020 Early research in Amyotrophic lateral sclerosis in South Korea, before September 2020 (1St Biotherapeutics pipeline, September 2020)